PMID- 31599421
OWN - NLM
STAT- MEDLINE
DCOM- 20201006
LR  - 20211015
IS  - 2284-0729 (Electronic)
IS  - 1128-3602 (Linking)
VI  - 23
IP  - 18
DP  - 2019 Sep
TI  - Polyoxometalate SbW9 regulates proliferation and apoptosis of NSCLC cells via 
      PTEN-dependent AKT signaling pathway.
PG  - 7959-7967
LID - 19012 [pii]
LID - 10.26355/eurrev_201909_19012 [doi]
AB  - OBJECTIVE: To explore the influence of polyoxometalate SbW9 on proliferation and 
      apoptosis of non-small cell lung cancer (NSCLC) cells and its mechanism. 
      MATERIALS AND METHODS: NSCLC cell lines A549 and PC9 were treated with 50 muM 
      polyoxometalate. Then, the proliferation of NSCLC cells was detected via 
      2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2H-t 
      tetrazolium hydroxide (XTT) assay and colony formation assay; the apoptosis of 
      NSCLC cells was detected via flow cytometry and terminal deoxynucleotidyl 
      transferase-mediated dUTP nick end labeling (TUNEL); and the expression of 
      apoptosis-related proteins, B-cell lymphoma-2 (Bcl-2), and Bcl-2 associated X 
      protein (Bax), was detected via Western blotting. Moreover, the protein 
      expression levels of phosphatase and tensin homolog deleted on chromosome ten 
      (PTEN), phosphorylated-protein kinase B (P-AKT) and total AKT (T-AKT) were 
      detected via Western blotting. RESULTS: The polyoxometalate inhibited the 
      proliferation of A549 and PC9 cells in a concentration-dependent manner (5-100 
      muM) (p<0.05), and it (50 muM) also inhibited the proliferation of both cells in a 
      time-dependent manner (0-72 h) (p<0.05). The results of colony formation assay 
      revealed that the polyoxometalate (50 muM) could significantly inhibit the colony 
      formation of A549 and PC9 cells (p<0.05). The results of flow cytometry and TUNEL 
      staining showed that the polyoxometalate (50 muM) significantly induced the 
      apoptosis of A549 and PC9 cells (p<0.05). According to further studies, the 
      polyoxometalate (50 muM) inhibited the expression of anti-apoptotic gene Bcl-2 and 
      promoted the expression of pro-apoptotic gene Bax. Besides, the Western blotting 
      results manifested that the polyoxometalate could activate the expression of PTEN 
      and inhibit the phosphorylation of downstream AKT (p<0.05). CONCLUSIONS: The 
      polyoxometalate can activate the expression of PTEN to inhibit the 
      phosphorylation of AKT, ultimately inhibiting the proliferation and inducing the 
      apoptosis of NSCLC cells. Therefore, the polyoxometalate is expected to become a 
      novel drug for the clinical treatment of NSCLC.
FAU - Sun, H-B
AU  - Sun HB
AD  - Department of Thoracic Surgery, China-Japan Union Hospital of Jilin University, 
      Changchun, China. xznjida@163.com.
FAU - Xu, L
AU  - Xu L
FAU - Wang, Z-X
AU  - Wang ZX
FAU - Zheng, Y
AU  - Zheng Y
FAU - Zhao, Y
AU  - Zhao Y
FAU - Yin, Y-Y
AU  - Yin YY
FAU - Han, X-L
AU  - Han XL
FAU - Xu, Z-N
AU  - Xu ZN
LA  - eng
PT  - Journal Article
PT  - Retracted Publication
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
RN  - 0 (BAX protein, human)
RN  - 0 (BCL2 protein, human)
RN  - 0 (Proto-Oncogene Proteins c-bcl-2)
RN  - 0 (Tungsten Compounds)
RN  - 0 (bcl-2-Associated X Protein)
RN  - 9IT35J3UV3 (Antimony)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 3.1.3.67 (PTEN Phosphohydrolase)
SB  - IM
RIN - Eur Rev Med Pharmacol Sci. 2021 Apr;25(7):2825. PMID: 33877676
MH  - A549 Cells
MH  - Antimony/*pharmacology
MH  - Apoptosis/*drug effects
MH  - Carcinoma, Non-Small-Cell Lung/*metabolism/pathology
MH  - Cell Line, Tumor
MH  - Cell Proliferation/*drug effects
MH  - Humans
MH  - In Situ Nick-End Labeling
MH  - Lung Neoplasms/*metabolism/pathology
MH  - PTEN Phosphohydrolase/*drug effects/metabolism
MH  - Phosphorylation
MH  - Proto-Oncogene Proteins c-akt/*drug effects/metabolism
MH  - Proto-Oncogene Proteins c-bcl-2/drug effects/metabolism
MH  - Tumor Stem Cell Assay
MH  - Tungsten Compounds/*pharmacology
MH  - bcl-2-Associated X Protein/drug effects/metabolism
EDAT- 2019/10/11 06:00
MHDA- 2020/10/07 06:00
CRDT- 2019/10/11 06:00
PHST- 2019/10/11 06:00 [entrez]
PHST- 2019/10/11 06:00 [pubmed]
PHST- 2020/10/07 06:00 [medline]
AID - 19012 [pii]
AID - 10.26355/eurrev_201909_19012 [doi]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2019 Sep;23(18):7959-7967. doi: 
      10.26355/eurrev_201909_19012.